CHI | Field trials | ||
Risk of adverse impact on COVID-19 response in the community | 1 to -1 | 2 to -2 | |
Risk of augmenting community spread | Risk of unintended infection from the viral strain | 1 to -1 | 0 to -1 |
Risk of other added SARS-CoV-2 infections in the community | -1 | 3 to -3 before approved vaccines were available; now that vaccines are available, 5 | |
Overall added risk from the trial to the local community and the consequent urgency of local community engagement | Lower | Higher, especially from now on |
The higher a number, the greater the risk.
CHI, controlled human infection.